Concept

Tumor development and progression are governed by two critical molecular layers: tumor-specific cell surface antigen expression that defines epithelial cancer identity and enables precision detection/therapy, and aberrant post-translational glycosylation modifications that drive metabolic reprogramming and immune evasion—two hallmarks of malignant transformation. Epithelial Cell Adhesion Molecule (EpCAM, CD326), a unique transmembrane glycoprotein overexpressed in nearly all epithelial-derived tumors, is the gold-standard marker for identifying epithelial cancers and isolating circulating tumor cells (CTCs). O-GlcNAcylation, a dynamic, nutrient-sensing serine/threonine glycosylation modification, orchestrates tumor metabolism and immune suppression via site-specific modification of key proteins like enolase 1 (ENO1), driving the Warburg effect and PD-L1-mediated T cell tolerance. Dissecting these complex tumor mechanisms and advancing precision oncology requires highly specific, application-optimized antibodies: EpCAM antibodies for epithelial tumor detection, CTC isolation and targeted therapy development, and O-GlcNAc-specific antibodies for unraveling glycosylation-mediated tumor immune evasion and metabolic reprogramming. As a global leader in life science reagents, ANT BIO PTE. LTD. delivers cutting-edge antibodies for both research areas via its Starter sub-brand (our flagship line for high-performance, rigorously validated antibodies): the S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (S0B2028) for epithelial tumor research, and the O-Linked N-Acetylglucosamine Recombinant Rabbit mAb (S0B0373) for glycosylation modification studies. Engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform, these antibodies offer ultra-specificity, exceptional multi-platform performance and batch-to-batch consistency—serving as indispensable gold-standard tools for tumor biology research, precision diagnosis, targeted therapy development and the dissection of tumor immune evasion mechanisms.

Research Frontiers

EpCAM and O-GlcNAc glycosylation research are at the forefront of modern tumor biology and precision oncology, spanning epithelial cancer detection, liquid biopsy, immune evasion mechanism dissection and targeted therapy innovation. ANT BIO PTE. LTD.’s specialized EpCAM and O-GlcNAc antibodies enable transformative discoveries in key high-impact research frontiers that are redefining our understanding of tumor development and revolutionizing cancer diagnosis and treatment:

EpCAM in Epithelial Tumor Precision Diagnosis & Therapy

1. Next-generation liquid biopsy: Engineering EpCAM antibody-based microfluidic and magnetic capture systems for high-sensitivity isolation and characterization of CTCs from peripheral blood, enabling single-cell analysis of CTC genetics and epigenetics for early cancer detection and minimal residual disease (MRD) monitoring.
2. EpCAM-targeted therapeutics: Developing EpCAM antibody-drug conjugates (ADCs), bispecific antibodies and CAR-T cell therapies for refractory epithelial cancers (e.g., colorectal, breast, pancreatic cancer), with a focus on reducing off-target toxicity and improving tumor selectivity.
3. Tumor stem cell research: Identifying and characterizing EpCAM-positive cancer stem cell (CSC) subpopulations in epithelial tumors, and exploring EpCAM-mediated signaling pathways that drive CSC self-renewal, metastasis and therapy resistance.
4. Companion diagnostic development: Validating EpCAM expression levels as a companion diagnostic biomarker to identify patients most likely to benefit from EpCAM-targeted therapies and immunotherapies for epithelial cancers.
5. Spatial transcriptomics integration: Combining EpCAM antibody-based tissue staining with spatial transcriptomics to map EpCAM expression in the tumor microenvironment (TME) and its correlation with immune cell infiltration and angiogenesis.

O-GlcNAc Glycosylation in Tumor Immune Evasion & Metabolic Reprogramming

1. Site-specific glycosylation function dissection: Uncovering how distinct O-GlcNAcylation sites on oncoproteins (e.g., ENO1 Thr19 vs. Ser249) drive divergent tumor functions, and identifying novel site-specific glycosylation targets for selective anti-tumor intervention.
2. Glycosylation-immune checkpoint crosstalk: Elucidating the molecular mechanisms by which O-GlcNAcylation regulates the stability and expression of immune checkpoint proteins (e.g., PD-L1, CTLA-4) in the TME, and exploring glycosylation targeting as a strategy to reverse immune checkpoint inhibitor (ICI) resistance.
3. Metabolic-immune synergy in the TME: Studying how O-GlcNAcylation-mediated metabolic reprogramming (Warburg effect) alters the TME microenvironment (e.g., lactate accumulation, acidosis) to inhibit anti-tumor immune cell function, and developing combination strategies to target both metabolic and immune pathways.
4. Glycosylation as a predictive biomarker: Validating O-GlcNAc modification levels of key proteins as predictive biomarkers for ICI response and chemotherapy efficacy, enabling personalized treatment decision-making for cancer patients.
5. OGT/OGA targeted therapy optimization: Developing small-molecule inhibitors of O-GlcNAc transferase (OGT) or O-GlcNAcase (OGA) that selectively block oncogenic glycosylation sites, and using O-GlcNAc antibodies to evaluate their efficacy and mechanism of action in preclinical cancer models.

Research Significance

EpCAM overexpression and aberrant O-GlcNAc glycosylation are defining molecular features of epithelial cancers—the most common form of human malignancy—with research into these targets driving a paradigm shift in precision oncology, from early detection to targeted therapy and immune evasion reversal. ANT BIO PTE. LTD.’s EpCAM and O-GlcNAc antibodies amplify the scientific and translational significance of this research, with far-reaching implications for cancer diagnosis, therapy and patient care:

EpCAM: The Gold-Standard Marker for Epithelial Cancer Precision Medicine

1. Universal epithelial tumor marker: EpCAM is overexpressed in nearly all epithelial-derived cancers (adenocarcinoma, squamous cell carcinoma) but minimally expressed in normal stromal tissue and non-epithelial tumors (sarcomas, lymphomas), making it the most specific and widely used marker for distinguishing epithelial cancers—a critical step in pathological diagnosis.
2. Enabling liquid biopsy: EpCAM is the primary target for CTC isolation from peripheral blood, a non-invasive liquid biopsy technology that has revolutionized cancer staging, MRD monitoring and treatment response assessment, particularly for metastatic epithelial cancers.
3. Ideal targeted therapy candidate: EpCAM’s cell surface localization and tumor-specific expression make it a prime target for antibody-based therapeutics (ADCs, CAR-T), with EpCAM-targeted therapies showing promising efficacy in preclinical and clinical studies for refractory epithelial cancers.
4. Key to cancer stem cell research: EpCAM is a core marker for identifying CSC subpopulations in epithelial tumors, which are responsible for tumor initiation, metastasis and therapy resistance—dissecting EpCAM-mediated CSC function is critical for developing curative cancer therapies.

O-GlcNAc Glycosylation: Unlocking the Mechanisms of Tumor Immune Evasion and Metabolic Reprogramming

1. A unifying regulator of tumor metabolism and immunity: O-GlcNAcylation is the first identified post-translational modification that drives both the Warburg effect (aerobic glycolysis) and PD-L1-mediated immune suppression via site-specific modification of a single protein (ENO1), providing a unifying target for combination therapy that simultaneously reverses metabolic reprogramming and immune evasion.
2. Novel mechanism of ICI resistance: Glycosylation-mediated PD-L1 stabilization is a newly discovered mechanism of ICI resistance in cancer; targeting O-GlcNAcylation offers a promising new strategy to restore anti-tumor immunity in patients who fail standard ICI therapy.
3. Nutrient-sensing link to tumorigenesis: O-GlcNAcylation acts as a cellular nutrient sensor, linking glucose and glutamine metabolism to oncogenic signaling—studying this connection reveals how dietary and metabolic factors contribute to tumor development, opening new avenues for metabolic cancer therapy.
4. Tumor-specific therapeutic target: O-GlcNAcylation is aberrantly upregulated in most cancers but tightly regulated in normal cells, making it a tumor-specific target with minimal off-target effects—an essential feature for developing safe and effective anti-tumor therapies.

Together, these antibody tools are enabling researchers to dissect the most complex molecular mechanisms of epithelial cancer and develop the next generation of precision diagnostics and therapeutics that will transform the care of cancer patients worldwide.

Related Mechanisms, Research Methods & Product Applications

1. EpCAM: Molecular Structure, Function and Tumor Expression Characteristics

Epithelial Cell Adhesion Molecule (EpCAM, CD326) is a unique 314-amino acid type I transmembrane glycoprotein encoded by the TACSTD1 (GA733-2) gene on human chromosome 4, with a molecular structure that does not belong to classical cell adhesion molecule families (integrins, selectins, cadherins). Its modular structure consists of three functional domains:

• A 242-amino acid extracellular domain containing an epidermal growth factor (EGF)-like domain and a thyroglobulin-like repeat sequence—critical for homotypic cell adhesion and receptor signaling, with three potential N-glycosylation sites leading to a molecular weight of 33–40 kDa (glycosylation-dependent).
• A 23-amino acid single transmembrane domain that anchors the protein to the cell membrane.
• A 26-amino acid short intracellular domain that mediates downstream signaling pathways regulating cell proliferation, migration and invasion.

EpCAM forms tetrameric multimers on the cell surface and exhibits tumor-specific expression patterns:

• Normal tissue expression: Restricted to the basolateral surface of normal epithelial cells with low expression levels, and absent in non-epithelial tissues (stroma, immune cells, connective tissue).
• Tumor expression: Markedly upregulated in nearly all epithelial-derived cancers (colorectal, breast, lung, pancreatic, ovarian cancer), with expression levels correlating with tumor grade, metastasis and poor prognosis.
• CSC expression: Highly expressed in EpCAM-positive CSC subpopulations in epithelial tumors, a small cell fraction responsible for tumor initiation, metastasis and therapy resistance.

2. EpCAM Antibodies: Key Applications in Tumor Diagnosis and Therapy

EpCAM-specific antibodies are the cornerstone of epithelial cancer research and clinical diagnostics, with diverse applications spanning pathological diagnosis, liquid biopsy, basic tumor biology and targeted therapy development:

Diagnostic Applications

1. Histopathological classification: Immunohistochemistry (IHC) staining for EpCAM in tumor tissue sections to distinguish epithelial-derived cancers from non-epithelial tumors (sarcomas, lymphomas)—a core diagnostic step in surgical pathology, often used in combination with cytokeratin (CK) antibodies.
2. Circulating tumor cell (CTC) detection: EpCAM antibody-based magnetic or microfluidic capture systems to isolate and count EpCAM-positive CTCs from peripheral blood, enabling non-invasive early cancer detection, tumor staging, MRD monitoring and treatment response assessment.
3. Minimal residual disease (MRD) monitoring: High-sensitivity EpCAM detection in post-treatment blood and tissue samples to assess the presence of residual tumor cells, guiding adjuvant therapy decisions and predicting cancer recurrence.
4. Serum tumor marker detection: Enzyme-linked immunosorbent assay (ELISA) using EpCAM antibodies to detect soluble EpCAM (sEpCAM) in patient serum, a potential biomarker for auxiliary diagnosis and efficacy monitoring of epithelial cancers.

Therapeutic and Research Applications

1. Targeted therapy development: EpCAM antibodies as the foundation for developing ADCs, bispecific antibodies and immunotoxins that deliver cytotoxic payloads specifically to EpCAM-positive tumor cells, minimizing systemic toxicity.
2. CAR-T cell therapy: EpCAM as a target antigen for engineering CAR-T cells that specifically recognize and kill EpCAM-positive epithelial tumor cells and CSCs— a promising therapy for refractory metastatic epithelial cancers.
3. Signal pathway dissection: Co-immunoprecipitation (Co-IP) and immunofluorescence (IF) using EpCAM antibodies to study EpCAM-mediated downstream signaling pathways (e.g., Wnt/β-catenin, PI3K/Akt) that regulate tumor cell proliferation, migration and invasion.
4. Cancer stem cell research: Flow cytometry (FACS) using fluorescently conjugated EpCAM antibodies to sort EpCAM-positive CSC subpopulations from tumor cell suspensions, enabling functional characterization of CSCs and the development of CSC-targeted therapies.
5. Tissue engineering and developmental biology: EpCAM antibodies to label and track epithelial cells in organoid culture, regenerative medicine and developmental biology research, studying epithelial cell differentiation and tissue formation.

3. O-GlcNAc Glycosylation: A Dynamic Nutrient-Sensing PTM Regulating Tumor Biology

O-GlcNAcylation is a reversible, intracellular glycosylation modification that involves the covalent attachment of a single N-acetylglucosamine (GlcNAc) moiety to serine/threonine residues of nuclear and cytoplasmic proteins, catalyzed by O-GlcNAc transferase (OGT) and reversed by O-GlcNAcase (OGA). Unlike other glycosylation modifications, O-GlcNAcylation:

• Is nutrient-dependent: Its levels are directly regulated by intracellular UDP-GlcNAc concentrations (a product of glucose and glutamine metabolism), acting as a cellular "nutrient sensor" that links metabolic status to cell signaling.
• Occurs in the nucleus and cytoplasm: In contrast to cell surface N/O-glycosylation, O-GlcNAcylation modifies intracellular proteins (transcription factors, signaling molecules, metabolic enzymes).
• Is dynamic and reversible: Similar to phosphorylation, it undergoes rapid cycles of addition and removal to regulate protein function in response to cellular stimuli.

In cancer cells, aberrant O-GlcNAcylation drives tumor development and progression by regulating key biological processes, with the most well-characterized example being the site-specific modification of ENO1:

• ENO1 Thr19 O-GlcNAcylation: Promotes ENO1 dimer formation and enhances its glycolytic enzyme activity, driving the Warburg effect (aerobic glycolysis) in tumor cells. This metabolic reprogramming produces large amounts of lactate, which accumulates in the TME and directly inhibits the cytotoxic function of T cells and natural killer (NK) cells.
• ENO1 Ser249 O-GlcNAcylation: Blocks the interaction between ENO1 and PD-L1, inhibiting the E3 ubiquitin ligase STUB1-mediated ubiquitination and degradation of PD-L1. This leads to abnormal PD-L1 accumulation on the tumor cell surface, which binds to PD-1 on T cells and suppresses T cell activation—inducing T cell tolerance and immune evasion.

This site-specific dual regulation creates a synergistic effect in the TME, combining metabolic reprogramming and immune suppression to create a tumor-permissive environment that enables cancer cell proliferation, survival and metastasis.

4. O-GlcNAc-Specific Antibodies: Indispensable Tools for Glycosylation and Tumor Immunology Research

O-GlcNAc-specific antibodies are the gold-standard tools for studying this dynamic PTM, enabling the detection, quantification and functional characterization of O-GlcNAcylation in tumor cells and the TME across a wide range of experimental platforms:

1. O-GlcNAc modification omics: Immunoprecipitation (IP) combined with mass spectrometry (MS) using O-GlcNAc antibodies to systematically identify and validate the global profile of O-GlcNAc-modified proteins in cancer cells and tissues under different physiological and pathological conditions.
2. Dynamic modification detection: Western blot (WB) and IF using O-GlcNAc antibodies to quantify O-GlcNAc modification levels in tumor cells in response to nutrient availability, growth factors and anti-tumor therapies, studying the dynamic regulation of this PTM.
3. Subcellular localization analysis: IHC and IF to map the subcellular distribution of O-GlcNAc-modified proteins in the nucleus and cytoplasm of tumor cells, and to study their localization changes in the TME.
4. Signaling pathway dissection: Co-IP and WB to study the cross-regulation between O-GlcNAcylation and phosphorylation—two major PTMs that compete or collaborate to regulate the function of transcription factors (e.g., c-Myc, Sp1) and signaling molecules (e.g., AKT, GSK-3β) in cancer cells.
5. Clinical sample analysis: IHC and WB using O-GlcNAc antibodies to detect O-GlcNAc modification levels in human tumor tissue samples, exploring their potential as diagnostic, prognostic and predictive biomarkers for cancer.
6. Drug development and evaluation: High-throughput screening of OGT/OGA inhibitors using O-GlcNAc antibodies, and evaluating the effects of these inhibitors on O-GlcNAcylation levels, tumor metabolism, immune evasion and tumor growth in preclinical cancer models.

ANT BIO PTE. LTD.’s Starter Antibodies: Core Products for Tumor Biology Research

ANT BIO PTE. LTD.’s Starter sub-brand delivers two industry-leading antibodies for EpCAM epithelial tumor research and O-GlcNAc glycosylation studies—both engineered on the proprietary S-RMab® recombinant rabbit monoclonal platform and rigorously validated for ultra-specificity, exceptional multi-platform performance and batch-to-batch consistency. These antibodies are optimized for the unique experimental and clinical needs of tumor biology research, precision oncology and cancer immunology, and serve as gold-standard tools for basic and translational cancer research worldwide.

1. S-RMab® EpCAM Recombinant Rabbit Monoclonal Antibody (S0B2028)

This high-performance antibody is specifically designed for epithelial tumor research and clinical pathology, with exceptional specificity for the EpCAM extracellular domain and clear membrane staining in formalin-fixed, paraffin-embedded (FFPE) tissue sections—making it the gold-standard tool for EpCAM detection.

Core Product Advantages

Key Research & Clinical Applications

• Epithelial tumor pathological diagnosis: Distinguishing epithelial-derived cancers from non-epithelial tumors (sarcomas, lymphomas) in FFPE tissue sections, used in combination with CK series antibodies for confirmatory diagnosis.
• Circulating tumor cell (CTC) detection: As a capture/detection antibody for enriching and identifying EpCAM-positive CTCs from peripheral blood—critical for liquid biopsy, prognostic assessment and treatment response monitoring.
• Cancer stem cell (CSC) research: FACS sorting of EpCAM-positive CSC subpopulations from tumor cell suspensions for functional characterization and CSC-targeted therapy development.
• EpCAM-targeted therapy research: Validating EpCAM expression in tumor models and clinical samples for ADC, bispecific antibody and CAR-T cell therapy development—including patient stratification and efficacy assessment.
• Developmental biology & tissue engineering: Labeling and tracking epithelial cells in organoid culture, regenerative medicine and developmental biology research to study epithelial cell differentiation and tissue formation.

2. O-Linked N-Acetylglucosamine Recombinant Rabbit mAb (S0B0373)

This ultra-specific antibody is the gold-standard tool for O-GlcNAc glycosylation modification research, with exceptional specificity for O-GlcNAc modifications on serine/threonine residues and broad target coverage across all O-GlcNAc-modified proteins—no protein sequence dependence required.

Core Product Advantages

Key Research Applications

• O-GlcNAc modification omics: IP-MS to systematically identify and validate O-GlcNAc-modified protein profiles in cancer cells/tissues under specific physiological/pathological conditions (e.g., nutrient deprivation, immune stimulation).
• Tumor signaling pathway dissection: Studying the cross-regulation between O-GlcNAcylation and phosphorylation in oncogenic signaling pathways (PI3K/Akt, MAPK, Wnt/β-catenin) to unravel the molecular mechanisms of tumor development.
• Metabolism-immune crosstalk research: Exploring how O-GlcNAcylation (a cellular nutrient sensor) regulates tumor metabolism (Warburg effect) and immune evasion (PD-L1 stabilization) in the TME.
• Cancer biomarker discovery: Detecting O-GlcNAc modification levels in human tumor samples to identify novel diagnostic, prognostic and predictive biomarkers for cancer and treatment response.
• Drug development: Screening and evaluating OGT/OGA inhibitors, and assessing their effects on O-GlcNAcylation levels, tumor growth and immune evasion in preclinical cancer models.
• Disease mechanism research: Studying aberrant O-GlcNAcylation in other human diseases (Alzheimer’s, diabetes, cardiovascular disease) beyond cancer.

Brand Mission of ANT BIO PTE. LTD.

At ANT BIO PTE. LTD., our core mission is to empower breakthroughs in tumor biology research, precision oncology and cancer immunology by delivering high-quality, highly specific and rigorously validated life science reagents and comprehensive solutions. As a leading global provider of research tools, we have built three specialized, complementary sub-brands that cover the full spectrum of life science research needs, creating a seamless one-stop procurement experience for academic researchers, pathologists, biotech companies, pharmaceutical institutions and translational research labs worldwide:

• Starter: Our flagship sub-brand for high-performance antibodies and affinity tools, offering tumor research antibodies (EpCAM S0B2028, O-GlcNAc S0B0373), prostate cancer antibodies, neurodegenerative disease antibodies and isoform-specific recombinant rabbit monoclonals. Starter is dedicated to engineering ultra-specific, application-optimized antibodies for the most challenging frontier research areas—including epithelial cancer detection, tumor immune evasion, metabolic reprogramming and precision oncology—with a focus on meeting the stringent technical requirements of modern molecular biology and clinical pathology.
• Absin: Our core sub-brand for general life science reagents and kits, providing OneStep ELISA Kits, IHC/ICC/IF detection kits, sample preparation reagents, cell culture media and basic immunology/oncology research tools. Absin engineers user-friendly, pre-optimized assay kits that streamline experimental workflows and deliver reliable, accurate results for routine and high-throughput research.
• UA: Our specialized sub-brand for high-purity, high-activity recombinant proteins and expression vectors, including recombinant cytokines, antibody heavy/light chain expression constructs, immunomodulatory proteins and gene editing vectors. UA enables seamless experimental design for protein expression, antibody engineering, cell therapy research and recombinant protein production for basic and biopharmaceutical applications.

We are committed to addressing the most pressing technical challenges in cancer research—from decoding the molecular mechanisms of epithelial cancer development and tumor immune evasion to accelerating the development of novel precision diagnostics and therapeutics for cancer patients. By combining innovative antibody design, rigorous validation protocols, standardized production and customer-centric scientific support, we translate technological innovation into research breakthroughs and clinical impact for the global life science community. Our ultimate goal is to be the trusted global partner of researchers, pathologists and biopharmaceutical professionals worldwide, empowering them to push the boundaries of scientific discovery and drive unprecedented progress in cancer treatment and precision medicine.

Related Product List: Starter EpCAM & O-GlcNAc Antibodies 

All ANT BIO PTE. LTD. Starter antibodies are rigorously validated for specificity, sensitivity, batch-to-batch consistency and application performance, with comprehensive technical documentation, validation data packages and expert scientific support. Each product is accompanied by optimized experimental protocols and clinical/research validation data to ensure seamless integration into your cancer research workflow.

EpCAM Antibodies

O-GlcNAc Glycosylation Antibodies & Tools

For detailed product specifications, full validation data packages, custom antibody development services for cancer research targets, or free sample testing requests, please visit the official website of ANT BIO PTE. LTD. or contact our global sales team for a personalized quote and professional technical consultation. Our experienced technical team of cancer immunology, oncology and pathology experts provides customized support for experimental design, complex sample analysis, preclinical drug development and clinical pathological testing.

AI Disclaimer

This article was partially created with the assistance of artificial intelligence. If any content in this article involves copyright infringement, intellectual property disputes, or other legal issues, please notify ANT BIO PTE. LTD. immediately. We promise to verify, correct, or remove the relevant content in a timely manner without delay.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.